Silvercrest Asset Management Group LLC Has $11.01 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Silvercrest Asset Management Group LLC lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 3.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 127,998 shares of the company’s stock after purchasing an additional 3,881 shares during the quarter. Silvercrest Asset Management Group LLC’s holdings in Novo Nordisk A/S were worth $11,010,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. M. Kulyk & Associates LLC grew its stake in Novo Nordisk A/S by 3.9% in the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company’s stock valued at $274,000 after buying an additional 119 shares during the last quarter. Center for Financial Planning Inc. grew its stake in Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after buying an additional 123 shares during the last quarter. Tradewinds Capital Management LLC grew its stake in Novo Nordisk A/S by 2.6% in the 4th quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company’s stock valued at $429,000 after buying an additional 124 shares during the last quarter. Exencial Wealth Advisors LLC grew its stake in Novo Nordisk A/S by 0.5% in the 4th quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company’s stock valued at $1,987,000 after buying an additional 124 shares during the last quarter. Finally, Indie Asset Partners LLC grew its stake in Novo Nordisk A/S by 4.2% in the 4th quarter. Indie Asset Partners LLC now owns 3,128 shares of the company’s stock valued at $269,000 after buying an additional 126 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on NVO shares. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 25th. Guggenheim lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 17th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. BMO Capital Markets restated a “market perform” rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Finally, BNP Paribas started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an “underperform” rating on the stock. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and an average price target of $135.00.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $64.35 on Friday. The company’s fifty day moving average is $67.31 and its two-hundred day moving average is $84.38. The firm has a market capitalization of $288.75 billion, a price-to-earnings ratio of 19.56, a P/E/G ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts’ consensus estimates of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.